Contraindications to Methotrexate in Ectopic Pregnancy

Absolute Contraindications

• Intrauterine pregnancy (coexisting or undesired methotrexate exposure to a viable IUP)
• Hemodynamically unstable patient
• Ruptured ectopic pregnancy
• Breastfeeding
• Immunodeficiency
• Moderate to severe anemia, leukopenia, or thrombocytopenia
• Known sensitivity/hypersensitivity to methotrexate
• Active pulmonary disease
• Active peptic ulcer disease
• Clinically significant hepatic or renal dysfunction

Relative Contraindications

• Ectopic mass >4 cm in size on transvaginal ultrasound
• Embryonic cardiac motion detected on transvaginal ultrasound
• Inability to comply with required follow-up (serial b-hCG monitoring, return visits)
• High initial b-hCG concentration (>5,000 mIU/mL) - associated with lower treatment success
• Refusal to accept blood transfusion if needed

Why these matter clinically

Recent evidence check

• PMID 37345445 - IPD meta-analysis comparing methotrexate vs. expectant management for tubal ectopic pregnancy (2023)
• PMID 40674737 - Systematic review/meta-analysis on methotrexate success in recurrent vs. primary ectopic pregnancy (2026)
• PMID 39384737 - Review of letrozole plus methotrexate as an alternative regimen (2024)

Mississippi Triple-Class Classification (HELLP Syndrome)

Classification

• Class I carries the highest risk of maternal morbidity (need for transfusion, renal failure, need for ventilatory support) and is managed most aggressively.
• Class III (sometimes called "partial HELLP") is milder and some patients may not require immediate delivery if remote from term and stable.

How it compares to the Tennessee classification

1. Microangiopathic hemolytic anemia (abnormal smear, low haptoglobin, elevated LDH)
2. LDH >600 IU/L (or 2x upper limit of normal) and AST >70 IU/L (or 2x ULN), or bilirubin >1.2 mg/dL
3. Platelet count <100,000/uL

Clinical use - the "Mississippi Protocol"

Context

Management of HELLP Syndrome

1. Initial stabilization (applies to all patients)

• Admission, preferably to an ICU or high-dependency obstetric unit given the risk of rapid, unpredictable deterioration - - Brenner and Rector's The Kidney.
• IV magnesium sulfate for seizure prophylaxis, as in severe preeclampsia/eclampsia. Therapeutic range 5-9 mg/dL; monitor for toxicity (loss of deep tendon reflexes, flushing, somnolence, decreased respiratory rate), especially with renal impairment - - Brenner and Rector's The Kidney; Harrison's Principles of Internal Medicine, 22nd ed.
• Blood pressure control (antihypertensives for severe range BP).
• Correct coagulopathy if clinically indicated - - Tintinalli's Emergency Medicine.
• Baseline and serial labs: CBC/platelets, LDH, haptoglobin, AST/ALT, bilirubin, creatinine, coagulation studies.

2. Delivery - the definitive treatment

• Prompt delivery is the management of choice, especially beyond 34 weeks' gestation, or at any gestational age if the mother or fetus is unstable - - Yamada's Textbook of Gastroenterology, 7th ed.
• Some authors recommend immediate delivery in all confirmed HELLP cases given the high rate of maternal complications - - Brenner and Rector's The Kidney.
• Expectant management (24-34 weeks) can be considered only if the mother is relatively stable and fetal status is reassuring, to allow time for fetal lung maturation with corticosteroids - close inpatient monitoring is mandatory since deterioration can be sudden.
• Mode of delivery (vaginal vs. cesarean) is based on obstetric factors, not HELLP itself.

3. Platelet transfusion

• Consider platelet transfusion to a target of 40,000-50,000/uL, particularly if cesarean delivery is anticipated or platelets are markedly low - - Yamada's Textbook of Gastroenterology.
• Plasma exchange/plasmapheresis should be considered in atypical presentations with severe thrombocytopenia (<30 x 10^9/L) that fail to improve after delivery, to distinguish from and treat overlapping TTP - - Comprehensive Clinical Nephrology, 7th ed.

4. Corticosteroids - the "Mississippi Protocol"

• The Mississippi protocol bundles corticosteroids + magnesium sulfate + tight systolic BP control; early initiation was associated with lower rates of disease progression/severity in an observational cohort of 190 patients.
• However, evidence for steroids treating HELLP itself (beyond fetal lung maturation) is mixed:
  • A Cochrane review found dexamethasone improved platelet count recovery but showed no difference in maternal morbidity/mortality or perinatal/infant death.
  • A more recent RCT similarly showed no benefit of high-dose dexamethasone on hard outcomes, though a post-hoc subgroup with platelets <50,000/uL may have shorter platelet recovery and hospital stay with steroids - further study needed - - Brenner and Rector's The Kidney.
  • Glucocorticoids retain a clear, separate role for fetal lung maturation in expectantly managed pregnancies <34 weeks.

5. Emerging/adjunct therapies (limited evidence)

• Eculizumab (complement C5 inhibitor) has been used off-label to prolong pregnancy in select cases, given pathophysiologic overlap with complement-mediated TMA - - Yamada's Textbook of Gastroenterology.
• Plasmapheresis for antepartum HELLP has only limited, mixed case-series data and carries a risk of worsening placental perfusion - not routinely recommended before delivery - - Brenner and Rector's The Kidney.

6. Postpartum course and recurrence

• HELLP usually resolves spontaneously after delivery within days, but delayed postpartum presentation occurs in up to 30% of cases despite no preeclampsia signs at delivery - continue monitoring after birth.
• Recurrence of HELLP itself in future pregnancies is uncommon, but these women carry a significantly elevated risk of preeclampsia in subsequent pregnancies, especially with underlying chronic hypertension.

Recent evidence check (systematic reviews/meta-analyses, last 2-3 years)

• PMID 39026148 (2024) and PMID 37937841 (2023) - both meta-analyses of corticosteroids in HELLP reinforce the textbook conclusion: steroids improve platelet counts but do not clearly improve hard maternal/perinatal outcomes, consistent with the Cochrane findings above.
• PMID 37150281 (2023) - systematic review of HELLP presenting before 23 weeks' gestation, a periviable scenario not detailed in the standard textbooks; if this is clinically relevant to a specific case, worth flagging separately since standard delivery-timing recommendations don't directly apply below viability.

Conservative Management of Ectopic Pregnancy

1. Expectant Management (Watchful Waiting)

• Hemodynamically stable, minimal or no symptoms
• Declining or plateauing serum b-hCG (a static or falling trend suggests the pregnancy is failing on its own)
• Low initial b-hCG (generally <200 IU/L is most favorable for spontaneous resolution; higher levels reduce success)
• No evidence of rupture, no significant free fluid
• Small ectopic mass, no cardiac activity
• Patient reliable for close follow-up with serial b-hCG until non-pregnant levels

2. Medical Management - Methotrexate

3. Conservative Surgery - Salpingostomy

• Unruptured ectopic pregnancy
• Desire for future fertility
• Damage to the contralateral fallopian tube (making tube preservation more important, since removing this tube would necessitate IVF for future pregnancy)

• Ipsilateral tubal patency after laparoscopic salpingostomy is about 84%
• Intrauterine pregnancy rates: ~60% after salpingostomy vs. comparable/54% after salpingectomy in some series, though randomized trials show no significant overall difference in future IUP rates between the two
• Repeat ectopic pregnancy is more common after salpingostomy than salpingectomy (~10% vs. 4%, OR 2.27) - the trade-off for tube preservation is a higher risk of recurrent ectopic pregnancy
• Risk of persistent trophoblastic tissue (retained viable trophoblast at the implantation site, usually medial to the incision) requiring post-op b-hCG surveillance and sometimes adjuvant methotrexate

Choosing between the three

• Clinical stability - rupture or instability mandates surgery (usually salpingectomy if damage is extensive)
• b-hCG trend and level - low/declining favors expectant management; moderate levels within contraindication limits favor methotrexate
• Ultrasound findings - mass size, cardiac activity
• Fertility goals and contralateral tube status - salpingostomy favored when the contralateral tube is damaged and future fertility is desired
• Ability to comply with follow-up - all conservative options require serial b-hCG monitoring to confirm resolution and detect persistent/recurrent disease

Recent evidence check

• PMID 37345445 (2023, IPD meta-analysis) - supports expectant management as comparable to methotrexate in appropriately selected patients.
• PMID 37443463 (2024, network meta-analysis) - confirms methotrexate's continued central role among medical options.
• PMID 37115078 (2023, meta-analysis) - reproductive outcomes after conservative vs. surgical treatment, generally consistent with the textbook data on tubal patency and pregnancy rates cited above.

Tennessee Classification (HELLP Syndrome)

Complete HELLP syndrome (Tennessee criteria)

1. Microangiopathic hemolytic anemia - abnormal peripheral blood smear (schistocytes), low serum haptoglobin, and elevated serum LDH
2. Elevated liver enzymes - serum LDH >600 IU/L (or >2x the laboratory upper limit of normal) AND serum AST >70 IU/L (or >2x ULN), OR serum bilirubin >1.2 mg/dL
3. Thrombocytopenia - platelet count <100,000/uL

Incomplete HELLP syndrome

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, ch. 40 (Box 40.1)

Tennessee vs. Mississippi at a glance

Gestational Diabetes Mellitus (GDM) - Definition

• Timing: Hyperglycemia is usually detected in the late second trimester (13-26 completed weeks) or third trimester (27-40 weeks), and resolves following delivery - - Goldman-Cecil Medicine, Int'l ed.
• Pathophysiology: Normal pregnancy causes physiologic insulin resistance because the placenta secretes diabetogenic hormones (human placental lactogen, growth hormone, corticotropin-releasing hormone, progesterone), producing roughly a 60% reduction in insulin sensitivity. In women with adequate pancreatic reserve, beta-cell hyperplasia compensates. GDM develops when the pancreas cannot overcome this physiologic insulin resistance despite compensatory beta-cell hyperplasia - - Goldman-Cecil Medicine.
• Prevalence: Roughly 5-6% of pregnancies in the US, though this varies from 1-25% depending on maternal ethnicity and which diagnostic criteria are applied - - Creasy & Resnik's Maternal-Fetal Medicine; Goldman-Cecil Medicine.
• Risk factors: Overweight/obesity, older maternal age (>30 years), family history of type 2 diabetes.

An important nuance: definitional controversy

• One-step approach (IADPSG/ADA): 75g OGTT, GDM diagnosed if any one value is met/exceeded (fasting ≥92 mg/dL, 1-hr ≥180 mg/dL, 2-hr ≥153 mg/dL) - lower thresholds, higher diagnosed prevalence.
• Two-step approach (Carpenter-Coustan, more common in the US per ACOG): 50g screening glucose challenge test followed by a 100g OGTT for confirmation if the screen is abnormal - stricter, fewer women diagnosed.

Downstream significance

• Nearly half of women with GDM develop type 2 diabetes within 10 years postpartum; a large meta-analysis (675,455 women) found a 7-fold increased risk of later diabetes.
• Women with GDM have a 50-85% higher cardiovascular disease risk, and the AHA classifies GDM history as a CVD risk factor independent of later T2DM development - - Creasy & Resnik's Maternal-Fetal Medicine.
• Fetal/neonatal risks include macrosomia, birth injury/shoulder dystocia, neonatal hypoglycemia and hyperbilirubinemia, and increased future risk of obesity and type 2 diabetes in the offspring.

Recent evidence check

• PMID 39578035 (2024) - meta-analysis linking different diagnostic criteria sets to adjusted risk of adverse pregnancy outcomes, reinforcing that the choice of diagnostic threshold materially changes both prevalence and predicted risk.
• PMID 40640901 (2025) - explores glycated albumin/fructosamine vs. HbA1c as alternative diagnostic markers, an active area of methodological research not yet part of standard definitions.